ArticleMicrobiology spectrum2026
Immune evasion, infectivity, and membrane fusion of SARS-CoV-2 variants LP.8.1.1, XEC.25.1, XFG, and NB.1.8.1.
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Emerging SARS-CoV-2 variants, with potentially enhanced immune evasion and transmissibility, pose a serious challenge to public health. This study provides a systematic characterization of the virological features of JN.1 descendant subvariants, including LP.8.1.1, KP.3, XEC.25.1, XFG, and NB.1.8.1, focusing on their infectivity, receptor binding, membrane fusion, and immune evasion capacity. Multiple JN.1 descendant variants exhibited reduced infectivity across various human cell lines, whereas XEC.25.1 and NB.1.8.1 demonstrated significantly enhanced cellular infectivity. JN.1 descendant variants retained the capability to infect cells expressing ACE2 orthologs from diverse mammalian species, indicating their persistent risk of zoonotic transmission. Notably, NB.1.8.1 exhibited the highest ACE2-binding affinity among all tested variants, while XEC.25.1 shows superior membrane fusion activity, particularly in cells expressing TMPRSS2. Serum neutralization assays revealed that LP.8.1.1, KP.3, XEC.25.1, XFG, and NB.1.8.1 exhibited enhanced immune evasion capabilities compared to the JN.1 strain, which was closely associated with their rapid transmission. These findings reveal that emerging JN.1 subvariants accelerate viral transmission by altering receptor-binding affinity, optimizing cellular entry efficiency, and enhancing immune evasion. Therefore, it is necessary to update vaccines and improve antiviral treatment strategies to meet the public health challenges posed by these variants. IMPORTANCE: SARS-CoV-2 JN.1 has continuously evolved during the epidemic, giving rise to multiple descendant variants. Currently, JN.1 sublineages NB.1.8.1, XFG, XEC.25.1, and LP.8.1.1 have emerged as the predominant circulating variants globally. The cellular infectivity, cross-species transmission potential, and immune evasion capacity of these emerging variants remain poorly characterized. This study employed a VSV pseudovirus system to characterize the virological features of JN.1 descendant subvariants. We found that the cellular infectivity of JN.1 descendant variants was significantly altered, which may be attributed to changes in receptor-binding affinity or membrane fusion activity. The emerging JN.1 subvariants retained the ability to infect cells expressing ACE2 orthologs from diverse species. Furthermore, the emerging variants LP.8.1.1, KP.3, XEC.25.1, XFG, and NB.1.8.1 exhibited enhanced immune evasion capabilities compared to the JN.1 strain. Our study underscores the importance of surveillance and virological research for emerging JN.1 descendant variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.